Douglas G. Cole - May 26, 2022 Form 4 Insider Report for Sigilon Therapeutics, Inc. (SGTX)

Role
Director
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Stock symbol
SGTX
Transactions as of
May 26, 2022
Transactions value $
$0
Form type
4
Date filed
5/27/2022, 05:00 PM
Previous filing
Jul 14, 2021
Next filing
Jun 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $0 +8.89K $0.00 8.89K May 26, 2022 Common Stock 8.89K $0.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023